Basis of Presentation

12 Months Ended

Dec. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Basis of Presentation

General

The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include the accounts of Fibrocell and its wholly owned subsidiaries. The accompanying Consolidated Financial Statements should be read in conjunction with the Notes to the Consolidated Financial Statements ("Notes"). All intercompany accounts and transactions have been eliminated in consolidation. The Company's foreign operations are immaterial and it has no unrealized gains or losses from the sale of investments. As a result, it does not have any items that would be classified as other comprehensive income in such a statement.

Reclassifications

The prior year financial statements contain certain reclassifications to the results of operations for the year ended December 31, 2014 to conform to the presentation for the year ended December 31, 2015 in this Form 10-K. Compensation and related expenses for manufacturing and facilities personnel of approximately $1.5 million were reclassified from selling, general and administrative expenses to research and development expenses for the year ended December 31, 2014. This reclassification was made in conjunction with the Company’s strategic shift away from the aesthetic market (LAVIV) and towards diseases affecting the skin, connective tissue and joints.    

On April 30, 2013, the Company completed a 25-for-1 reverse stock split.  All common share and per share data included in these Consolidated Financial Statements reflect this reverse stock split.